Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Conventional isoelectric focusing. In gel slabs and capillaries and immobilized pH gradients.

Righetti PG, Fasoli E, Righetti SC.

Methods Biochem Anal. 2011;54:379-409. Review. No abstract available.

PMID:
21954787
2.

Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast.

Gatti L, Hoe KL, Hayles J, Righetti SC, Carenini N, Bo LD, Kim DU, Park HO, Perego P.

BMC Genomics. 2011 Jan 19;12:44. doi: 10.1186/1471-2164-12-44.

3.

A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells.

Milli A, Cecconi D, Campostrini N, Timperio AM, Zolla L, Righetti SC, Zunino F, Perego P, Benedetti V, Gatti L, Odreman F, Vindigni A, Righetti PG.

Biochim Biophys Acta. 2008 Nov;1784(11):1702-10. doi: 10.1016/j.bbapap.2008.04.022. Epub 2008 May 4.

PMID:
18503786
4.

Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.

Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, Leone R, Apostoli P, Lanzi C, Zunino F.

Mol Cancer Ther. 2008 Mar;7(3):679-87. doi: 10.1158/1535-7163.MCT-07-0450.

5.

Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells.

Righetti SC, Perego P, Carenini N, Zunino F.

Cancer Lett. 2008 May 8;263(1):140-4. doi: 10.1016/j.canlet.2007.12.024. Epub 2008 Feb 7.

PMID:
18261847
6.

Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study.

Marengo E, Robotti E, Bobba M, Milli A, Campostrini N, Righetti SC, Cecconi D, Righetti PG.

Anal Bioanal Chem. 2008 Mar;390(5):1327-42. doi: 10.1007/s00216-008-1837-y. Epub 2008 Jan 29.

PMID:
18224487
7.

Molecular alterations of cells resistant to platinum drugs: role of PKCalpha.

Righetti SC, Perego P, Carenini N, Corna E, Dal Bo L, Cedrola S, La Porta CA, Zunino F.

Biochim Biophys Acta. 2006 Jan;1763(1):93-100. Epub 2006 Jan 6.

8.

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, Zupi G, Del Bufalo D, Balsari A, Zunino F.

Eur J Cancer. 2005 May;41(8):1213-22.

PMID:
15911246
9.

Proteomic approaches for studying chemoresistance in cancer.

Righetti PG, Castagna A, Antonioli P, Cecconi D, Campostrini N, Righetti SC.

Expert Rev Proteomics. 2005 Apr;2(2):215-28. Review.

PMID:
15892566
10.

A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.

Castagna A, Antonioli P, Astner H, Hamdan M, Righetti SC, Perego P, Zunino F, Righetti PG.

Proteomics. 2004 Oct;4(10):3246-67.

PMID:
15378690
11.

Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.

Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F.

Int J Cancer. 2003 Jul 10;105(5):617-24.

12.

Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.

Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, Righetti SC, Zuco V, Zunino F.

Cell Death Differ. 2002 Dec;9(12):1352-9.

13.

Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.

Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F.

Clin Cancer Res. 2002 Dec;8(12):3904-9.

14.

Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells.

Beretta GL, Righetti SC, Lombardi L, Zunino F, Perego P.

Ultrastruct Pathol. 2002 Sep-Oct;26(5):331-4.

PMID:
12396244
15.

Single-strand conformation polymorphism for p53 mutation by a combination of neutral pH buffer and temperature gradient in capillary electrophoresis.

Gelfi C, Vigano A, De Palma S, Righetti PG, Righetti SC, Corna E, Zunino F.

Electrophoresis. 2002 May;23(10):1517-23.

PMID:
12116163
16.

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.

Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F.

Cancer Lett. 2002 Jan 10;175(1):17-25.

PMID:
11734332
17.

Single-strand conformation polymorphism analysis by capillary zone electrophoresis in neutral pH buffer.

Gelfi C, Viganó A, Curcio M, Righetti PG, Righetti SC, Corna E, Zunino F.

Electrophoresis. 2000 Mar;21(4):785-91.

PMID:
10733223
18.

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F.

Br J Cancer. 1999 Aug;80(12):1912-9.

19.

Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.

Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.

Cell Growth Differ. 1999 Jul;10(7):473-8.

20.

Optimized detection of DNA point mutations by double gradient denaturing gradient gel electrophoresis.

Cremonesi L, Carrera P, Cardillo E, Fumagalli A, Lucchiari S, Ferrari M, Righetti SC, Righetti PG, Gelfi C.

Clin Chem Lab Med. 1998 Dec;36(12):959-61.

PMID:
9915229
21.

Validation of double gradient denaturing gradient gel electrophoresis through multigenic retrospective analysis.

Cremonesi L, Carrera P, Fumagalli A, Lucchiari S, Cardillo E, Ferrari M, Righetti SC, Zunino F, Righetti PG, Gelfi C.

Clin Chem. 1999 Jan;45(1):35-40.

PMID:
9895335
22.

Detection of p53 point mutations by double-gradient, denaturing gradient gel electrophoresis.

Gelfi C, Righetti SC, Zunino F, Della Torre G, Pierotti MA, Righetti PG.

Electrophoresis. 1997 Dec;18(15):2921-7.

PMID:
9504831
23.

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R, Zunino F.

J Natl Cancer Inst. 1997 Aug 20;89(16):1217-23.

PMID:
9274917
24.

Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.

Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F.

Clin Cancer Res. 1997 Jun;3(6):955-61.

25.

Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines.

Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N, Bedogné B, Broome E, Krajewski S, Reed JC, Zunino F.

Apoptosis. 1997;2(6):540-8.

PMID:
14646525
26.

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F.

Cancer Res. 1996 Feb 15;56(4):689-93.

27.

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.

Cancer Res. 1996 Feb 1;56(3):556-62.

Supplemental Content

Loading ...
Support Center